Clinical Trials Go Live

The FDA has started proof-of-concept trials that expose endpoints and safety signals to reviewers as studies run. The experiment could cut review delays without removing the hard work of sound clinical evidence.

7 sources / Updated August 26, 2026

YouTubeU.S. Food and Drug Administration
Advancing Real-Time Clinical Trials
Official FDA briefing introducing two proof-of-concept trials and the agency's planned real-time clinical-trial pilot.
Open original
What changed
The FDA is testing direct, ongoing access to endpoints and safety signals in two drug studies rather than waiting for conventional reporting packages. The proof-of-concept work includes lymphoma and small-cell lung cancer programs with major sponsors and academic medical centers. This changes the review cadence: regulators may be able to see trends while a study is active, ask sharper questions earlier, and reduce periods when completed work waits in a queue before the next formal handoff.
WebU.S. Food and Drug AdministrationU.S. Food and Drug AdministrationFDA announces major steps to implement real-time clinical trialsPrimary announcement naming the proofs of concept, participating trials, pilot request for information, and intended regulatory workflow.Read original
What remains unproved
Continuous visibility does not make raw trial data clean, comparable, or clinically meaningful. Sites still need correct enrollment, protocol adherence, source verification, adverse-event handling, and protection from biased interim interpretation. It is also unclear how often reviewers will act on live signals, what standards sponsors must meet, and whether added dashboards reduce work or create another reporting layer. Faster review must be measured against decision quality, patient safety, staff burden, and the risk of premature conclusions.
WebU.S. Department of Health and Human ServicesU.S. Department of Health and Human ServicesHHS launches clinical trials reform initiativeBroader federal program covering early-trial timelines, platform approaches, AI-supported safety work, and domestic clinical research capacity.Read original
What to watch
The next evidence should show actual time saved at each step, the number and quality of early interventions, and whether trial sites spend less time on duplicate reporting. Watch the pilot rules for audit trails, access controls, data standards, and how the FDA handles incomplete or changing records. The most convincing result would be a shorter total development timeline with no increase in protocol deviations, missed safety events, or burdens placed on patients and front-line study staff.
WebAxiosAxiosFDA to use AI to track clinical trials in real timeIndependent account of the two trials, the agency's time-saving claims, and the distinction between live data access and the full development process.Read original

Loading collection…

Advancing Real-Time Clinical Trials

What changed

What remains unproved

What to watch